437 related articles for article (PubMed ID: 23587333)
1. KIT D816V mutation burden does not correlate to clinical manifestations of indolent systemic mastocytosis.
Broesby-Olsen S; Kristensen T; Vestergaard H; Brixen K; Møller MB; Bindslev-Jensen C;
J Allergy Clin Immunol; 2013 Sep; 132(3):723-728. PubMed ID: 23587333
[TBL] [Abstract][Full Text] [Related]
2. Serum tryptase correlates with the KIT D816V mutation burden in adults with indolent systemic mastocytosis.
Kristensen T; Broesby-Olsen S; Vestergaard H; Bindslev-Jensen C; Møller MB;
Eur J Haematol; 2013 Aug; 91(2):106-11. PubMed ID: 23621866
[TBL] [Abstract][Full Text] [Related]
3. Diagnosis of Primary Mast Cell Disorders in Anaphylaxis: Value of KIT D816V in Peripheral Blood.
De Puysseleyr LP; Ebo DG; Elst J; Faber MA; Poorten MV; Van Gasse AL; Bridts CH; Mertens C; Van Houdt M; Hagendorens MM; Verlinden A; Vermeulen K; Maes MB; Berneman ZN; Sabato V
J Allergy Clin Immunol Pract; 2021 Aug; 9(8):3176-3187.e3. PubMed ID: 33975032
[TBL] [Abstract][Full Text] [Related]
4. Prospective evaluation of the diagnostic value of sensitive KIT D816V mutation analysis of blood in adults with suspected systemic mastocytosis.
Kristensen T; Vestergaard H; Bindslev-Jensen C; Mortz CG; Kjaer HF; Ollert M; Møller MB; Broesby-Olsen S;
Allergy; 2017 Nov; 72(11):1737-1743. PubMed ID: 28432683
[TBL] [Abstract][Full Text] [Related]
5. The KIT D816V expressed allele burden for diagnosis and disease monitoring of systemic mastocytosis.
Erben P; Schwaab J; Metzgeroth G; Horny HP; Jawhar M; Sotlar K; Fabarius A; Teichmann M; Schneider S; Ernst T; Müller MC; Giehl M; Marx A; Hartmann K; Hochhaus A; Hofmann WK; Cross NC; Reiter A
Ann Hematol; 2014 Jan; 93(1):81-8. PubMed ID: 24281161
[TBL] [Abstract][Full Text] [Related]
6. KIT D816V-mutated bone marrow mesenchymal stem cells in indolent systemic mastocytosis are associated with disease progression.
Garcia-Montero AC; Jara-Acevedo M; Alvarez-Twose I; Teodosio C; Sanchez-Muñoz L; Muñiz C; Muñoz-Gonzalez JI; Mayado A; Matito A; Caldas C; Morgado JM; Escribano L; Orfao A
Blood; 2016 Feb; 127(6):761-8. PubMed ID: 26622064
[TBL] [Abstract][Full Text] [Related]
7. Circulating KIT D816V mutation-positive non-mast cells in peripheral blood are characteristic of indolent systemic mastocytosis.
Kristensen T; Broesby-Olsen S; Vestergaard H; Bindslev-Jensen C; Møller MB;
Eur J Haematol; 2012 Jul; 89(1):42-6. PubMed ID: 22469616
[TBL] [Abstract][Full Text] [Related]
8. Detection of the KIT D816V mutation in peripheral blood of systemic mastocytosis: diagnostic implications.
Jara-Acevedo M; Teodosio C; Sanchez-Muñoz L; Álvarez-Twose I; Mayado A; Caldas C; Matito A; Morgado JM; Muñoz-González JI; Escribano L; Garcia-Montero AC; Orfao A
Mod Pathol; 2015 Aug; 28(8):1138-49. PubMed ID: 26067933
[TBL] [Abstract][Full Text] [Related]
9. An immature immunophenotype of bone marrow mast cells predicts for multilineage D816V KIT mutation in systemic mastocytosis.
Teodosio C; García-Montero AC; Jara-Acevedo M; Alvarez-Twose I; Sánchez-Muñoz L; Almeida J; Morgado JM; Matito A; Escribano L; Orfao A
Leukemia; 2012 May; 26(5):951-8. PubMed ID: 22051531
[TBL] [Abstract][Full Text] [Related]
10. Characterization of CD34
Mayado A; Teodosio C; Dasilva-Freire N; Jara-Acevedo M; Garcia-Montero AC; Álvarez-Twose I; Sánchez-Muñoz L; Matito A; Caldas C; Muñoz-González JI; Henriques A; Sánchez-Gallego JI; Escribano L; Orfao A
Allergy; 2018 Jun; 73(6):1294-1304. PubMed ID: 29331029
[TBL] [Abstract][Full Text] [Related]
11. Nonaggressive systemic mastocytosis (SM) without skin lesions associated with insect-induced anaphylaxis shows unique features versus other indolent SM.
Alvarez-Twose I; Zanotti R; González-de-Olano D; Bonadonna P; Vega A; Matito A; Sánchez-Muñoz L; Morgado JM; Perbellini O; García-Montero A; De Matteis G; Teodósio C; Rossini M; Jara-Acevedo M; Schena D; Mayado A; Zamò A; Mollejo M; Sánchez-López P; Cabañes N; Orfao A; Escribano L; ;
J Allergy Clin Immunol; 2014 Feb; 133(2):520-8. PubMed ID: 23921094
[TBL] [Abstract][Full Text] [Related]
12. The impact of sensitive KIT D816V detection on recognition of indolent Systemic Mastocytosis.
De Matteis G; Zanotti R; Colarossi S; De Benedittis C; Garcia-Montero A; Bonifacio M; Sartori M; Aprili F; Caruso B; Paviati E; Carli G; Perbellini O; Zamò A; Bonadonna P; Pizzolo G; Guidi G; Martinelli G; Soverini S
Leuk Res; 2015 Mar; 39(3):273-8. PubMed ID: 25582384
[TBL] [Abstract][Full Text] [Related]
13. KIT D816V mutation-positive cell fractions in lesional skin biopsies from adults with systemic mastocytosis.
Kristensen T; Broesby-Olsen S; Vestergaard H; Bindslev-Jensen C; Møller MB
Dermatology; 2013; 226(3):233-7. PubMed ID: 23774045
[TBL] [Abstract][Full Text] [Related]
14. A new humanized in vivo model of KIT D816V+ advanced systemic mastocytosis monitored using a secreted luciferase.
Bibi S; Zhang Y; Hugonin C; Mangean MD; He L; Wedeh G; Launay JM; Van Rijn S; Würdinger T; Louache F; Arock M
Oncotarget; 2016 Dec; 7(50):82985-83000. PubMed ID: 27783996
[TBL] [Abstract][Full Text] [Related]
15. Clinical and Molecular Diagnostic Evaluation of Systemic Mastocytosis in the South-Eastern Hungarian Population Between 2001-2013--A Single Centre Experience.
Marton I; Krenács L; Bagdi E; Bakos A; Demeter J; Borbényi Z
Pathol Oncol Res; 2016 Apr; 22(2):293-9. PubMed ID: 26545382
[TBL] [Abstract][Full Text] [Related]
16. The KIT D816V allele burden predicts survival in patients with mastocytosis and correlates with the WHO type of the disease.
Hoermann G; Gleixner KV; Dinu GE; Kundi M; Greiner G; Wimazal F; Hadzijusufovic E; Mitterbauer G; Mannhalter C; Valent P; Sperr WR
Allergy; 2014 Jun; 69(6):810-3. PubMed ID: 24750133
[TBL] [Abstract][Full Text] [Related]
17. Improved detection of the KIT D816V mutation in patients with systemic mastocytosis using a quantitative and highly sensitive real-time qPCR assay.
Kristensen T; Vestergaard H; Møller MB
J Mol Diagn; 2011 Mar; 13(2):180-8. PubMed ID: 21354053
[TBL] [Abstract][Full Text] [Related]
18. Systemic mastocytosis associated with chronic idiopathic myelofibrosis: a distinct subtype of systemic mastocytosis associated with a [corrected] clonal hematological non-mast [corrected] cell lineage disorder carrying the activating point mutations KITD816V and JAK2V617F.
Sotlar K; Bache A; Stellmacher F; Bültmann B; Valent P; Horny HP
J Mol Diagn; 2008 Jan; 10(1):58-66. PubMed ID: 18165278
[TBL] [Abstract][Full Text] [Related]
19. Adverse Prognostic Impact of the
Naumann N; Lübke J; Baumann S; Schwaab J; Hoffmann O; Kreil S; Dangelo V; Reiter L; Bugert P; Kristensen T; Sotlar K; Haselmann V; Schneider S; Metzgeroth G; Weiss C; Popp HD; Fabarius A; Hofmann WK; Cross NCP; Reiter A; Jawhar M
Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33806359
[TBL] [Abstract][Full Text] [Related]
20. Molecular quantification of tissue disease burden is a new biomarker and independent predictor of survival in mastocytosis.
Greiner G; Gurbisz M; Ratzinger F; Witzeneder N; Class SV; Eisenwort G; Simonitsch-Klupp I; Esterbauer H; Mayerhofer M; Müllauer L; Sperr WR; Valent P; Hoermann G
Haematologica; 2020; 105(2):366-374. PubMed ID: 31018976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
